Forecast
The analysts' average price target is €15.47 (+344.54%). The median is €18.20 (+422.99%).
| Buy |
Â
8 |
| Hold |
Â
2 |
| Sell |
Â
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Nuvation Bio reports strong launch of IBTROZI and positive Safusidenib data
At the Cantor Fitzgerald Healthcare Conference, Nuvation Bio said IBTROZI reached roughly 20% of the theoretical ROS1 market in its first year and uptake in first-line therapy continues to grow. The company holds $700 million in cash and considers itself well positioned financially to fund commercialization and its pipeline. Safusidenib showed a 79% non‑progression rate and a 52% response rate at 3 years, and multiple studies are planned through 2029. Management forecasts a peak sales potential for IBTROZI of $4–5 billion at full market penetration, while warning of development risks and emphasizing disciplined capital deployment. » More on de.investing.com
Nuvation Bio receives FDA fast-track for safusidenib and Cantor-Fitzgerald starts coverage with 12 USD target
The FDA granted safusidenib fast-track status for the treatment of IDH1‑mutated gliomas based on phase 2 data (confirmed objective response rate 51.9%, median progression‑free survival not yet reached, 36‑month PFS 79.1%). The designation enables more intensive interaction with the agency and a possible rolling review, reducing regulatory risk while the phase 3 SIGMA study continues to enroll. Cantor Fitzgerald initiated coverage with an “Overweight” rating and set a price target of 12 USD, with revenue forecasts of roughly 965 million USD for IBTROZI and about 1.9 billion USD for safusidenib. The news pushed the stock higher intraday (rise to 7.02 USD). » More on de.investing.com
Nuvation Bio receives FDA fast-track for safusidenib in IDH1 gliomas
The FDA has granted fast-track designation to safusidenib, an oral investigational candidate from Nuvation Bio for the treatment of IDH1‑mutant gliomas. The decision is based on phase‑2 data (J201) showing a confirmed objective response rate of 51.9% and a 36‑month progression‑free survival of 79.1%; median PFS has not yet been reached. Nuvation is currently recruiting for the registrational phase‑3 SIGMA trial, which will evaluate safusidenib as maintenance therapy versus placebo after standard treatment in IDH1‑mutant astrocytomas with high‑risk features (about 300 patients). Safusidenib is a selective inhibitor of mutant IDH1 designed to penetrate the blood–brain barrier; no new long‑term safety signals have been reported. » More on de.investing.com
Nuvation Bio receives Overweight from JPMorgan after robust second quarter
Nuvation Bio reports a solid second quarter and cash of $661 million. JPMorgan initiated coverage with an "Overweight" rating and a $13 price target, supported by expected first-line uptake. The bank sees additional revenue potential in prevalence-driven gene sequencing and in the pipeline around Safusidenib; the company remains focused on targeted cancer therapies and has a strengthened capital base. » More on finanzen.net
Nuvation Bio reports Q2 revenue growth for IBTROZI and expands safusidenib trials
Nuvation Bio posted Q2 total revenue of $31.7 million with U.S. IBTROZI product sales of $23.2 million, a 25% sequential increase as use shifts toward first-line ROS1 patients. Management highlighted stronger first-line uptake and longer treatment durations, supported by favorable TRUST-I and patient-reported outcomes. The company expanded safusidenib development with a Phase III trial in newly diagnosed Grade 2 IDH1-mutant glioma and a Phase II study for post-vorasidenib patients, citing durable Phase II results. Nuvation ended June with $661 million in cash and securities and raised about $279.1 million via convertible notes, which management says supports operations through profitability and the anticipated safusidenib launch. » More on finance.yahoo.com
Financials
In the last quarter, Nuvation Bio Inc Ordinary Shares - Class A had revenue of €39.68M and net profit of -€36.99M
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 39.68M | 254.97% |
| Gross profit | 29.15M | 250.14% |
| Net profit | -36.99M | 22.19% |
| EBITDA | -31.08M | 33.39% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €1.21B |
Number of shares | 352.02M |
52-week high/low | €8.87 - €3.43 |
| Dividends | No |
Beta | 1.73 |
P/E ratio | -9.58 |
PEG ratio | -0.20 |
P/B ratio | 5.83 |
P/S ratio | 6.60 |
Company profile
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
| Name | Nuvation Bio Inc Ordinary Shares - Class A |
| CEO | David T. Hung |
| Headquarters | New York City,
ny USA |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 08/26/2020 |
| Employees | 310 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NYSE | NUVB |